

Press Release



ASKA Pharmaceutical launches DroEthi® COMBINATION TABLETS for the treatment of Dysmenorrhea

TOKYO, June 16, 2022 - ASKA Pharmaceutical Co., Ltd. (Headquarter: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Headquarter: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi), announced today that the dysmenorrhea treatment DroEthi® COMBINATION TABLETS (Drospirenone/ Ethinylestradiol) has been listed in the NHI drug price standard today, and is to be launched on June 17, the effective date of the drug price standard.

Product Information

Product name: DroEthi® COMBINATION TABLETS

Generic name: Drospirenone/ Ethinylestradiol

Indication: Dysmenorrhea

Date of launch: June 17, 2022

The impact of this matter on our business performance has already been incorporated into our consolidated financial forecast for the fiscal year ending March 31, 2023.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp